Women are told to survive menopause. We should be preparing for longevity.

Hot flashes. Sleep disruption. Mood swings. Brain fog.

These are the symptoms we talk about. These are the symptoms we manage, suppress, and wait out.

But while the conversation stays focused on how women feel during perimenopause and menopause, something much larger is happening underneath, quietly, measurably, and with consequences that extend decades into the future.

The medical system has taught women to survive menopause. It's time we start using it to prepare for what comes next.

This is not a hormonal inconvenience. It is a cardiovascular inflection point.

Cardiovascular disease is the leading cause of death in women worldwide. Not breast cancer. Not any other condition. Heart disease, in every region, across every income level, regardless of ethnicity.

And yet most women don't know this. In a 2019 AHA survey, only 44% of American women identified heart disease as their number one health threat, a decline from 65% a decade earlier.

Part of the reason is cultural. For decades, women's health has been built almost entirely around reproductive health. And that work matters, it has saved lives. But it has also created a blind spot. Most women know they should get their Pap smear and their mammogram. They schedule those appointments. They show up.

But how many of them have ever seen a cardiologist? How many know their blood pressure numbers, not just whether they were "fine" at their last check-up, but their actual values? How many know their ApoB, their Lp(a), their HbA1c, their visceral fat percentage?

These are not obscure metrics. They are the numbers that will determine whether a woman develops heart disease, diabetes, or a stroke in her 60s. And most women have never been told they exist.

Here's what the data shows clearly: women typically develop coronary heart disease several years later than men, and the menopausal transition contributes significantly to the increase in that risk. The protection that estrogen provides, to arterial walls, to lipid metabolism, to inflammation, does not disappear gradually. It shifts during perimenopause, a transition that typically begins between the ages of 45 and 55 and can last 7 to 14 years, involving a decline in estradiol of approximately 60%.

That drop is not cosmetic. Estrogen helps maintain the flexibility of arterial walls, promotes healthy blood flow, and contributes to increasing HDL cholesterol. A significant decline can lead to reduced vascular elasticity, lipid metabolism abnormalities, and accelerated atherosclerosis.

What's actually changing in your body

The menopausal transition triggers a cascade of metabolic changes that most standard check-ups don't capture, and most women are never told about.

Body composition shifts. Postmenopausal women have 36% more thoracic fat and 49% greater intra-abdominal fat compared with premenopausal women, independent of age and total fat mass. This is not about weight gain from lifestyle choices. It is a hormonally driven redistribution toward visceral fat, the kind most closely associated with cardiometabolic risk.

Insulin resistance rises. As estrogen declines, a series of metabolic changes takes place, including increasing visceral fat, insulin resistance, dyslipidemia, and hypertension, that significantly increases the risk of cardiovascular disease. This often happens before any symptom appears, and before any standard blood test flags it.

Bone loss accelerates. Accelerated bone loss begins during perimenopause, yet clinical detection often occurs too late for effective intervention. Studies suggest that up to 1 in 4 women experience particularly rapid bone mineral density loss during this transition, placing them at significantly elevated fracture risk later in life.

Vascular aging speeds up. Structural carotid artery remodeling is most evident during the late perimenopausal stage, and midlife women undergoing the menopausal transition show more rapid increases in aortic stiffness than women who remain premenopausal.

The myth of "your labs are normal"

Here's what I see repeatedly in clinical practice: a woman in her late 40s comes in feeling off, fatigue, weight gain around the waist, disrupted sleep, low energy. Her standard bloodwork comes back "within normal range." She is told everything is fine.

But the standard panel wasn't designed to catch what perimenopause does to metabolism in its early stages.

The markers that matter in this transition, fasting insulin, HOMA-IR, ApoB, Lp(a), high-sensitivity CRP, DEXA-based body composition, VO2 max, are rarely included in a routine annual check-up. And yet they are precisely the ones that tell you whether your physiology is on a healthy trajectory or quietly drifting toward disease.

Normal is not the same as optimal. And in this window of life, the difference between the two matters enormously.

The window that changes everything

Perimenopause and early menopause represent something that medicine consistently underestimates: an opportunity.

Women in perimenopause already show early indicators of hypertension, oxidative stress, and endothelial dysfunction, making this the most relevant moment for intervention, not years later when disease is already established.

The evidence is consistent: lifestyle interventions, targeted diagnostics, and personalized strategies implemented during this transition have a meaningfully greater impact than the same interventions applied a decade later, once cardiovascular or metabolic disease is already present.

This is what preventive medicine should look like, not managing disease, but changing the trajectory before it begins.

Four things worth doing now

1. Go beyond the standard panel.

Most routine check-ups measure total cholesterol, fasting glucose, and basic metabolic markers. But current cardiovascular prevention guidelines, including those from the European Society of Cardiology and the American Heart Association, recommend also assessing ApoB and Lp(a), which are superior predictors of cardiovascular risk and should be measured at least once in every adult. Adding HbA1c helps detect insulin dysregulation before it becomes diabetes. High-sensitivity CRP can help reclassify risk in women who fall into an intermediate category. If your doctor hasn't mentioned these, it's worth asking.

2. Ask about your bone and body composition, not just your weight.

Guidelines recommend bone density screening for postmenopausal women, yet many women arrive at that conversation too late. Getting a baseline DEXA scan during perimenopause gives you something more valuable than a diagnosis: it gives you a starting point to protect. Beyond bone, understanding your lean mass and visceral fat, not just the number on the scale, is increasingly recognized as clinically relevant in cardiometabolic risk assessment, even if it hasn't yet made its way into standard screening protocols everywhere.

3. Take muscle seriously, the evidence is strong.

The American Heart Association, the European Society of Cardiology, and the Menopause Society all recommend resistance training as a core component of cardiovascular prevention and healthy aging. In perimenopause specifically, it is one of the most impactful interventions available: it preserves insulin sensitivity, slows bone loss, maintains lean mass, and reduces cardiovascular risk, simultaneously. Two sessions per week is the minimum the evidence supports. More is better.

4. Don't rely on a single snapshot.

A one-time blood test tells you where you are today. What matters more is the direction you're heading. Longitudinal tracking, repeated bloodwork over time, continuous physiological monitoring, and structured follow-up, allows you and your physician to detect trends before they become problems. Wearable technology is an emerging tool in this space, and while formal guideline recommendations are still catching up to the evidence, the clinical logic is sound: physiology that is measured consistently is physiology that can be managed proactively.

The bottom line

Menopause is not something to get through. It is a biological signal, and one of the most important clinical moments in a woman's life.

The women who will age well in their 60s, 70s, and beyond are the ones who took their physiology seriously in their 40s and early 50s. Not because they followed every wellness trend, but because they had real data, real answers, and a plan built around evidence.

That's not surviving menopause. That's preparing for longevity.

Antonela Costa is a cardiologist and the Co-founder and Chief Medical Officer of Thyme, a preventive, evidence-based health program that accepts members seeking to extend their healthspan through deep medical assessment, longitudinal tracking, and personalized interventions. She believes the future of medicine is anticipatory, not reactive.

Connect with Antonela on LinkedIn · hello@thymelife.ai